{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:35:05Z","timestamp":1792643705607,"version":"4.5.0"},"reference-count":31,"publisher":"Japan Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1507\/endocrj.ej16-0624","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T18:06:05Z","timestamp":1496858765000},"page":"735-747","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study"],"prefix":"10.1507","volume":"64","author":[{"given":"Shigeyuki","family":"Tahara","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Nippon Medical School, Tokyo 113-8602, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Murakami","sequence":"additional","affiliation":[{"name":"Oncology development & Medical affairs, Novartis Pharma K.K., Tokyo 105-6333, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Oncology development & Medical affairs, Novartis Pharma K.K., Tokyo 105-6333, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimatsu","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S (2011) Clinical, quality of life, and economic value of acromegaly disease control. <i>Pituitary<\/i> 14: 284-294.","DOI":"10.1007\/s11102-011-0310-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, <i>et al<\/i>. (2014) Acromegaly: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab<\/i> 99: 3933-3951.","DOI":"10.1210\/jc.2014-2700"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, <i>et al<\/i>. (2009) Guidelines for acromegaly management: an update. <i>J Clin Endocrinol Metab<\/i> 94: 1509-1517.","DOI":"10.1210\/jc.2008-2421"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Melmed S (2006) Medical progress: Acromegaly. <i>N Engl J Med<\/i> 355: 2558-2573.","DOI":"10.1056\/NEJMra062453"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ayuk J, Stewart SE, Stewart PM, Sheppard MC (2002) Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. <i>J Clin Endocrinol Metab<\/i> 87: 4142-4146.","DOI":"10.1210\/jc.2001-011913"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, <i>et al<\/i>. (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. <i>J Clin Endocrinol Metab<\/i> 86: 2779-2786.","DOI":"10.1210\/jc.86.6.2779"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, <i>et al<\/i>. (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. <i>J Clin Endocrinol Metab<\/i> 91: 1397-1403.","DOI":"10.1210\/jc.2005-2347"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, <i>et al<\/i>. (2007) Long-term (up to 18 years) effects on GH\/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. <i>Clin Endocrinol (Oxf)<\/i> 67: 282-289.","DOI":"10.1111\/j.1365-2265.2007.02878.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Carmichael JD, Bonert VS, Nuno M, Ly D, Melmed S (2014) Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. <i>J Clin Endocrinol Metab<\/i> 99: 1825-1833.","DOI":"10.1210\/jc.2013-3757"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, <i>et al<\/i>. (2012) Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. <i>J Clin Endocrinol Metab<\/i> 97: 1589-1597.","DOI":"10.1210\/jc.2011-2508"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Neggers SJ, Muhammad A, van der Lely AJ (2016) Pegvisomant treatment in acromegaly. <i>Neuroendocrinology<\/i> 103: 59-65.","DOI":"10.1159\/000381644"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Bex M, Abs R, T&rsquo;Sjoen G, Mockel J, Velkeniers B, <i>et al<\/i>. (2007) AcroBel--the Belgian registry on acromegaly: a survey of the &lsquo;real-life&rsquo; outcome in 418 acromegalic subjects. <i>Eur J Endocrinol<\/i> 157: 399-409.","DOI":"10.1530\/EJE-07-0358"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Schofl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, <i>et al<\/i>. (2013) Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. <i>Eur J Endocrinol<\/i> 168: 39-47.","DOI":"10.1530\/EJE-12-0602"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Colao A, Bronstein MD, Freda P, Gu F, Shen CC, <i>et al<\/i>. (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. <i>J Clin Endocrinol Metab<\/i> 99: 791-799.","DOI":"10.1210\/jc.2013-2480"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, <i>et al<\/i>. (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. <i>Lancet Diabetes Endocrinol<\/i> 2: 875-884.","DOI":"10.1016\/S2213-8587(14)70169-X"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, <i>et al<\/i>. (2015) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. <i>Pituitary<\/i> 18: 385-394.","DOI":"10.1007\/s11102-014-0585-6"},{"key":"17","unstructured":"17. Novartis Pharma AG. Novartis drug Signifor approved in EU, marking an advance for patients with inadequately controlled acromegaly. 2014. Available at: https:\/\/www.novartis.com\/news\/media-releases\/novartis-drug-signiforr-approved-eu-marking-advance-patients-inadequately (last accessed November 2015)."},{"key":"18","unstructured":"18. Novartis Pharma AG. Novartis gains FDA approval for Signifor LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder. 2014. Available at: https:\/\/www.novartis.com\/news\/media-releases\/novartis-gains-fda-approval-signiforr-lar-treat-patients-acromegaly-rare-and (last accessed November 2015)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Bronstein MD, Fleseriu M, Neggers S, Colao A, Sheppard M, <i>et al<\/i>. (2016) Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. <i>BMC Endocr Disord<\/i> 16: 16.","DOI":"10.1186\/s12902-016-0096-8"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. <i>Trends Endocrinol Metab<\/i> 24: 238-246.","DOI":"10.1016\/j.tem.2012.11.007"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Oki Y, Inoue T, Imura M, Tanaka T, Genma R, <i>et al<\/i>. (2009) Investigation into the efficacy and safety of octreotide LAR in Japanese patients with acromegaly: Shizuoka study. <i>Endocr J<\/i> 56: 1095-1101.","DOI":"10.1507\/endocrj.K09E-172"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Shimatsu A, Teramoto A, Hizuka N, Kitai K, Ramis J, <i>et al<\/i>. (2013) Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism. <i>Endocr J<\/i> 60: 651-663.","DOI":"10.1507\/endocrj.EJ12-0417"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, <i>et<\/i> <i>al<\/i>. (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. <i>Clin Endocrinol (Oxf)<\/i> 66: 859-868.","DOI":"10.1111\/j.1365-2265.2007.02825.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Colao A, Auriemma RS, Pivonello R, Kasuki L, Gadelha MR (2016) Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. <i>Pituitary<\/i> 19: 235-247.","DOI":"10.1007\/s11102-015-0684-z"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R (2009) Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. <i>J Clin Endocrinol Metab<\/i> 94: 3746-3756.","DOI":"10.1210\/jc.2009-0941"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Shimatsu A, Nagashima M, Hashigaki S, Ohki N, Chihara K (2016) Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly. <i>Endocr J<\/i> 63: 337-347.","DOI":"10.1507\/endocrj.EJ15-0619"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Moyes VJ, Metcalfe KA, Drake WM (2008) Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. <i>Eur J Endocrinol<\/i> 159: 541-545.","DOI":"10.1530\/EJE-08-0306"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. <i>Eur J Endocrinol<\/i> 146: 707-716.","DOI":"10.1530\/eje.0.1460707"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, <i>et al<\/i>. (1999) Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. <i>Diabetes<\/i> 48: 77-85.","DOI":"10.2337\/diabetes.48.1.77"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, <i>et al<\/i>. (2013) Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. <i>Diabetes Care<\/i> 36: 1789-1796.","DOI":"10.2337\/dc12-1235"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, <i>et al<\/i>. (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. <i>J Clin Endocrinol Metab<\/i> 98: 3446-3453.","DOI":"10.1210\/jc.2013-1771"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/64\/7\/64_EJ16-0624\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T14:51:19Z","timestamp":1569423079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/64\/7\/64_EJ16-0624\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej16-0624","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}